Prilenia

Huntington’s disease is a rare genetic condition that causes nerve cells in the brain to decay over time. ?? The therapeutic field has been riddled with trial failures and abandoned studies. Only yesterday, Sage Therapeutics binned its once-promising Huntington’s program. ??? ?? However, with the EMA’s ongoing review of Prilenia’ pridopidine and recent encouraging results for uniQure’s AMT-130, Wave Life Sciences’ WVE-003, and Roche and Ionis Pharmaceuticals, Inc.’ tominersen, effective treatments seem to be on their way. ??? Read our latest article to find out what treatments are in store to treat the genetic condition! ?? https://lnkd.in/dAi4nyaq #huntingtonsdisease #rarediseases #geneticdisorders #genetictherapies #therapeuticadvances #biotechinnovation #neurologicalresearch

Thank you to all of our sponsors for continuing to support the HD community. #letstalkabouthd

Thank you Huntington's Disease Society of America (HDSA) for all you do in helping to harness the power of the #Huntingtonsdisease community in providing the patient perspective around symptoms and the impact the condition has on their life, and current approaches to treatment. Prilenia is proud to be an active partner in these important efforts.

Meet Brianna. She is sharing her family’s story to bring greater understanding of #Huntingtonsdisease and more research into treatment options.? Learn more about Brianna and her family at: https://lnkd.in/dp2qc3bt

Congratulations to Huntington Study Group and the entire HD community on a fantastic and busy #HSG2024 meeting! It was a busy couple of days for Prilenia too, with 5 posters (which can be seen here: https://lnkd.in/dvDqgv24), an oral presentation, a panel appearance on Family Day and loads of activity at our exhibition table.

Prilenia is delighted to have been able to help make this important Scottish Huntington's Association event happen for the HD community in Scotland!

Wonderful to see many from the HD community coming together, to further understand the research progress being made, at the Huntington Study Group Family day! Prilenia’s Seth Rotberg, MNM will be there connecting with as many people as possible.

Today is the start of Huntington Study Group 2024! Prilenia has plenty of #pridopidine data to talk about, and we have a stellar team in attendance who would love to chat. Come say hi at exhibit table #4.

?? New Webinar Video Available! Our latest webinar, “Research Insights: Latest Updates on Ongoing Studies,” is now available on our website and YouTube channel! Professor ?sa Petersén and experts from Prilenia, uniQure, PTC Therapeutics, Inc. and Wave Life Sciences shared exciting updates on clinical trials for Huntington’s disease. ?Catch up on the latest research insights and Q&A session here ? https://bit.ly/4e8mA2H #HuntingtonsDisease #ClinicalTrials #EHAWebinar #ResearchUpdates

NOV 13-15th: Join us for our 7th Annual ALS Research Symposium! Come gather with us from afar (held via Zoom so that anyone can attend easily from anywhere in the world), for our highly anticipated 3-day annual conference & listen in on presentations & talks from many of the world’s most prominent leaders in ALS research. On DAY 1 (11/13), 12 renowned ALS keynote speakers will give talks on important ALS topics including: The current clinical trials landscape, Innovation in trial design, New approaches to understanding sporadic ALS, miRNA’s, Somatic mosaicism, IPSCs modeling, the ALS exposome, subclassification, using neurofilament in clinical trials, ALS risk factors, outcome measures, ALL ALS, & more, from these esteemed researchers: Sabrina Paganoni, MD, PhD, Jeremy Shefner, MD, PhD, FAAN, Melanie Quintana, PhD, James Berry, MD, MPH, Jaime Raymond, MPH, Stephanie Melillo Fradette, PharmD, Ammar Al-Chalabi, PhD, Eran Hornstein, PhD, Justin Ichida, PhD, Eva Feldman, MD, PhD, Zinan Zhou, PhD, Dame Pamela Shaw, MD, FAAN, along w/moderators, Dr.’s Sabrina Paganoni and Robert Brown. On DAY 2 (11/14), presentations will be given from 19 members of the ALS pharma industry about current trials for which they are currently working or have recently completed towards effective treatments for ALS. We’ll hear from Acelot, Aclipse Therapeutics, Amylyx Pharmaceuticals, Arbor Technologies, Axoltis Pharma, Eikonizo Therapeutics, Kadimastem Ltd., Leal Therapeutics, Mitochon Pharmaceuticals, Inc., Modality.AI, Neurizon, NeuroSense Therapeutics, OrphAI Therapeutics, PLL Therapeutics, Prilenia, Spinogenix, Inc., Transposon Therapeutics, Inc., uniQure, Zydus Group Lifesciences. Day 2 will be moderated by James Berry, MD, MPH, and Fernando Vieira, MD. On DAY 3 (11/15), Indu Navar & EverythingALS, along with Leigh Hochberg, MD, PhD from The Ctr for Neurotech & Neuro-Recovery at MGH will converse with industry leaders from renowned companies including Compass AI, Critical Path Institute (C-Path), MGH, MIT, Passio AI, Regeneron, Microsoft, Modality, Temple University, and more.?The focus will be on sharing the effects & outcomes of the transformative power of collaboration between tech companies, pharmaceutical giants, and academic institutions. Explore how AI & neurotechnology are driving innovation & accelerating the development of new treatments and technologies for ALS. With immense gratitude to our Symposium Sponsors: Mitsubishi Tanabe Pharma America, Amylyx Pharmaceuticals, Biogen, Sanofi, Spinogenix, Inc., and QurAlis. This conference would not be possible without your generosity! All are welcome & reg is free but required at https://lnkd.in/gi2yUywH . #ALS #ALSResearchSymposium #ALSconference #ALSGlobalSymposium #ALSVirtualSymposium #AllAreWelcome #ALSONEResearchSymposium #RegisterForFree